Mereo BioPharma (MREO) Liabilities and Shareholders Equity (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $40.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $40.6 million, down 40.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $202.8 million (down 38.48% YoY), and the FY2025 annual result was $45.9 million, down 39.89% from the prior year.
• Liabilities and Shareholders Equity slipped to $40.6 million in Q1 2026 per MREO's latest filing, from $45.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $96.1 million in Q2 2024 and troughed at $40.6 million in Q1 2026.
• A 5-year average of $66.6 million and a median of $66.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity plunged 54.57% in 2022, then grew 22.14% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $77.4 million in 2022, then decreased by 14.1% to $66.5 million in 2023, then gained by 14.87% to $76.4 million in 2024, then plunged by 39.89% to $45.9 million in 2025, then retreated by 11.55% to $40.6 million in 2026.
• Business Quant data shows MREO's Liabilities and Shareholders Equity at $40.6 million in Q1 2026, $45.9 million in Q4 2025, and $53.6 million in Q3 2025.